Industry News

Search Articles:

FDA accepts BLA for subcutaneous formulation of Herceptin
Halozyme Therapeutics announced the FDA has accepted a BLA from Genentech for a subcutaneous formulation of trastuzumab (Herceptin®) in its FDA-approved breast cancer indications. This is a co-formulation with Halozyme's proprietary recombinant human hyaluronidase enzyme (ENHANZE®).July 11, 2018